ArticleProceedings of the National Academy of Sciences of the United States of America1993
A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 83 citations in OpenAlex.
- VNpj viruses · 2025Article
- Atypical Asparagine Deamidation of NW Motif Significantly Attenuates the Biological Activities of an Antibody Drug Conjugate.Antibodies (Basel, Switzerland) · 2023Article
- Computationally Designed Cyclic Peptides Derived from an Antibody Loop Increase Breadth of Binding for Influenza Variants.Structure (London, England : 1993) · 2020Article
- Peptide Antiviral Strategies as an Alternative to Treat Lower Respiratory Viral Infections.Frontiers in immunology · 2019Review
- Many Routes to an Antibody Heavy-Chain CDR3: Necessary, Yet Insufficient, for Specific Binding.Frontiers in immunology · 2018Article
- Potent peptidic fusion inhibitors of influenza virus.Science (New York, N.Y.) · 2017Article
- A cell-penetrating antibody fragment against HIV-1 Rev has high antiviral activity: characterization of the paratope.The Journal of biological chemistry · 2014Article
- The structural basis of antibody-antigen recognition.Frontiers in immunology · 2013Review
- β-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma.The Journal of biological chemistry · 2012Article
- Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.Translational oncology · 2010Article
- Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity.PloS one · 2009Article
- Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities.PloS one · 2008Article
- Genetic and structural determinants of virus neutralizing antibodies.Immunologic research · 2001Review
- Molecular determinants of polyreactive antibody binding: HCDR3 and cyclic peptides.Clinical and experimental immunology · 2000Article
- Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice.Journal of virology · 1998Article
- Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles.Journal of virology · 1996Article
- The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6.The EMBO journal · 1994Article
- Granulocyte-macrophage colony-stimulating factor mimicry and receptor interactions.Immunologic research · 1994Article
- From esoteric theory to therapeutic antibodies.Applied biochemistry and biotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A complementarity-determining region (CDR) of the mouse monoclonal antibody (mAb) F58 was constructed with specificity to a neutralization-inducing region of human immunodeficiency virus type 1 (HIV-1). The mAb has its major reactivity to the amino acid sequence I--GPGRA in the V3 viral envelope region. All CDRs including several framework amino acids were synthesized from the sequence deduced by cloning and sequencing mAb F58 heavy- and light-chain variable domains. Peptides derived from the third heavy-chain domain (CDR-H3) alone or in combination with the other CDR sequences competed with F58 mAb for the V3 region. The CDR-H3 peptide was chemically modified by cyclization and then inhibited HIV-1 replication as well as syncytium formation by infected cells. Both the homologous IIIB viral strain to which the F58 mAb was induced and the heterologous SF2 strain were inhibited. This synthetic peptide had unexpectedly potent antiviral activity and may be a potential tool for treatment of HIV-infected persons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.